A5020623160- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Asthma and respiratory diseases
- Health Systems, Economic Evaluations, Quality of Life
- Mast cells and histamine
- Health and Medical Research Impacts
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Antimicrobial Peptides and Activities
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Statistical Methods in Clinical Trials
- Single-cell and spatial transcriptomics
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Melanoma and MAPK Pathways
National Center for Tumor Diseases
2022-2024
Heidelberg University
2022-2024
University Hospital Heidelberg
2022-2024
Technical University of Munich
2019-2023
German Cancer Research Center
2022-2023
John Wiley & Sons (United States)
2020
Hudson Institute
2020
University of Freiburg
2019
Praxis für Hämatologie und Onkologie
2019
Klinikum rechts der Isar
2019
•Dynamic changes in ctDNA can be used to predict tumor response therapeutic regimens oncology.•LB-RECIST have been proposed and the context of clinical trials.•Several challenges exist for applicability need addressed a more standardized approach. Current evaluation treatment solid tumors depends on dynamic diameters as measured by imaging. However, these only detected when there are enough macroscopic volume, which limits usability radiological criteria evaluating earlier stages disease...
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers obtained FDA approval for targeted therapies immunotherapies. Those include BRAFV600E mutations, RET fusions, NTRK high mutation burden (TMB), deficient mismatch repair/high microsatellite instability (dMMR/MSI-High)....
Abstract As part of the COGNITION diagnostic registry program, residual tumor material after neoadjuvant therapy (NAT) patients with early breast cancer (eBC), who are still at high-risk for relapse NAT, is analyzed by next generation sequencing to identify biomarkers and actionable alterations. This strategy aims stratify subsequent genomics-guided therapies reduce significant risk metastatic dissemination hence improve disease-free survival. COGNITION-GUIDE a multicenter umbrella...
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which limited number patients are eligible due to age comorbidity. Combination therapy venetoclax azacitidine (5-AZA) seems be promising approach in myeloid malignancies, but data from HMA lacking. Furthermore, considerable concern combination regimens elderly...
COGNITION (Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials) is a diagnostic registry trial that employs genomic transcriptomic profiling biomarkers in high risk relapse after standard neoadjuvant chemotherapy (NACT) guide genomics-driven targeted post-neoadjuvant therapy.At National Center Tumor Diseases Heidelberg were biopsied before starting NACT, residual tumors NACT...
<b><i>Background:</i></b> Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, German health insurance system allows application reimbursement off-label drug use. Here, we describe current...
Targeting the cell cycle machinery represents a rational therapeutic approach in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Despite substantial response rates, clinical use of PLK inhibitor volasertib has been hampered by elevated side effects such as neutropenia infections.The primary objective was to analyse whether reduced dose able limit toxic on healthy haematopoiesis while retaining its effect.Bone marrow mononuclear cells (BMMNCs) patients with...
Abstract Background: The concept of precision oncology is nowadays increasingly implemented into clinical practice but predominantly restricted to the metastatic setting limiting benefits prolongation progression-free-survival (PFS). Implementation at an earlier disease stage with less tumor burden, heterogeneity and a higher capacity lesions inform on molecular landscape holds promise impact cure rates. Methods: prospective COGNITION/-GUIDE platform encompasses COGNITION diagnostic...
<div>Abstract<p>Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers obtained FDA approval for targeted therapies immunotherapies. Those include <i>BRAF V600E</i> mutations, <i>RET</i> fusions, <i>NTRK</i> high mutation...
Abstract Background: Biomarker-driven trials have led to multiple FDA tissue-agnostic approvals. We aimed explore the clinic-genomic landscape of alterations currently actionable by targeted therapies. Methods: mined AACR Project GENIE extract data about three molecular targets on list approvals (RET fusions, NTRK and BRAFV600E mutations). Results: Among 137401 patients in database (153,834 samples), 4506 samples harbored mutations (3%), 390 had fusions (0.3%), 375 RET (0.2%) (Table 1)....
Abstract Monitoring ctDNA by liquid biopsies seems to represent the perfect match for precision oncology and its cornerstone clinical framework: molecular tumour board (MTB). Detecting scrutinising success of targeted therapies or tracking and, that matter, addressing therapy with evolutive nature a are some main advancements one considers be important MTB. One challenge is correlating estimated allele frequency each identified genetic alteration determined analysing sequencing results...
Hypereosinophilia represents a heterogenous group of severe medical conditions characterized by elevated numbers eosinophil granulocytes in peripheral blood, bone marrow or tissue. Treatment options for hypereosinophilia remain limited despite recent approaches including IL-5-targeted monoclonal antibodies and tyrosine kinase inhibitors.To understand aberrant survival patterns pharmacologic intervention, we BCL-2-regulated apoptosis signaling testing BCL-2 family expression levels as well...
<div>Abstract<p>Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers obtained FDA approval for targeted therapies immunotherapies. Those include <i>BRAF V600E</i> mutations, <i>RET</i> fusions, <i>NTRK</i> high mutation...